Open    Access



The Role of Homocysteine and Other Clinical Laboratory Markers in Assessing Cardiovascular Risk in Patients on Hemodialysis



Author(s)

Irena Ivanova Gencheva-Angelova, Adelaida Lazarova Ruseva and Pavlina Dimitrova Yordanova-Laleva

Full-Text PDF XML     669 Views

DOI:10.17265/1934-7391/2016.01.007

Cardiovascular diseases constitute approximately 50% of deaths among dialysis patients in the USA and Europe. The increase in traditional and nontraditional cardiovascular risk factors in determining the high mortality of patients with end-stage renal disease (ESRD) is complicated due to the high frequency of risk factors in these patients. Some laboratory markers like homocysteine, albumin, cholesterol, triglycerides, LDL-cholesterol, and creatinine could be efficient in marking the risk of cardiovascular disease in these patients. We use Roche assay tests, based on routinely principles to determine this laboratory parameters used in the clinical laboratory. All laboratory parameters we measured on a biochemistry auto analyser Cobas Integra 400 at the clinical laboratory of University Hospital—Pleven. Using a statistical program a research was done on the quantitative characteristics and prognostic capabilities of homocysteine and other biochemical parameters. We determined the diagnostic specificity and sensitivity of our lab performance against vascular disease (heart attack or stroke) by ROC curves. For each of the observed values of biochemical parameters we calculated the diagnostic sensitivity and specificity. The threshold values for which the parameters have the highest sensitivity and specificity have been concluded. Summary of diagnostic value of parameters to judge the coefficient AUC—area under the curve, for cholesterol, LDL, triglycerides, albumin, it was a significant (P < 0.05). Homocysteine and the rest of the studied by us laboratory parameters can be regarded as laboratory markers of choice for assessing the risk of heart attack or stroke in patients on dialysis.

Homocysteine, albumin, end-stage renal disease, cardiovascular risk factors